1. Home
  2. JQC vs TBPH Comparison

JQC vs TBPH Comparison

Compare JQC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JQC
  • TBPH
  • Stock Information
  • Founded
  • JQC 2003
  • TBPH 2013
  • Country
  • JQC United States
  • TBPH United States
  • Employees
  • JQC N/A
  • TBPH N/A
  • Industry
  • JQC Finance Companies
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • JQC Finance
  • TBPH Health Care
  • Exchange
  • JQC Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • JQC 753.9M
  • TBPH 699.0M
  • IPO Year
  • JQC N/A
  • TBPH N/A
  • Fundamental
  • Price
  • JQC $5.06
  • TBPH $18.81
  • Analyst Decision
  • JQC
  • TBPH Strong Buy
  • Analyst Count
  • JQC 0
  • TBPH 4
  • Target Price
  • JQC N/A
  • TBPH $24.25
  • AVG Volume (30 Days)
  • JQC 714.6K
  • TBPH 569.5K
  • Earning Date
  • JQC 01-01-0001
  • TBPH 11-10-2025
  • Dividend Yield
  • JQC 11.13%
  • TBPH N/A
  • EPS Growth
  • JQC N/A
  • TBPH N/A
  • EPS
  • JQC N/A
  • TBPH 0.58
  • Revenue
  • JQC N/A
  • TBPH $80,327,000.00
  • Revenue This Year
  • JQC N/A
  • TBPH $79.82
  • Revenue Next Year
  • JQC N/A
  • TBPH N/A
  • P/E Ratio
  • JQC N/A
  • TBPH $32.54
  • Revenue Growth
  • JQC N/A
  • TBPH 27.12
  • 52 Week Low
  • JQC $4.82
  • TBPH $7.90
  • 52 Week High
  • JQC $5.65
  • TBPH $18.96
  • Technical
  • Relative Strength Index (RSI)
  • JQC 46.48
  • TBPH 68.84
  • Support Level
  • JQC $5.08
  • TBPH $17.50
  • Resistance Level
  • JQC $5.00
  • TBPH $18.58
  • Average True Range (ATR)
  • JQC 0.04
  • TBPH 0.99
  • MACD
  • JQC 0.00
  • TBPH 0.16
  • Stochastic Oscillator
  • JQC 57.89
  • TBPH 98.49

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: